Anders Sjalander
Overview
Explore the profile of Anders Sjalander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mickelsson M, Ekblom K, Stefansson K, Sjalander A, Naslund U, Hultdin J
Clin Chem Lab Med
. 2025 Feb;
PMID: 40021473
Objectives: We examined the magnitude of transcription errors in lipid variables in the VIPVIZA study and assessed whether education among the research personnel reduced the error frequency at follow-up. We...
2.
Hultin M, Sjalander A, Werner M, Hultberg P, Ragnarsson O, Skoglund I, et al.
Lakartidningen
. 2025 Jan;
122.
PMID: 39876695
There are four paths to a Swedish medical license. A shared agreement exists for those converting from a European license to recognize qualifications granted in the respective countries mutually. Swedish...
3.
Mickelsson M, Ekblom K, Stefansson K, Liv P, Sjalander A, Naslund U, et al.
Lipids Health Dis
. 2025 Jan;
24(1):18.
PMID: 39844181
Background: The ABO blood group system has shown an association with cardiovascular disease. The susceptibility to CVD is proposed to be partly mediated by dyslipidaemia in non-O individuals. Previous studies...
4.
Welander F, Renlund H, Sjalander A
Clin Kidney J
. 2024 Oct;
17(8):sfae206.
PMID: 39421237
Background: Patients with chronic kidney disease (CKD) and atrial fibrillation (AF) on oral anticoagulants (OACs) are at high risk of bleeding. Determinants of major bleeding risk in OAC users with...
5.
Holmberg H, Glader E, Naslund U, Carlberg B, Sonnerstam E, Norberg M, et al.
Eur J Clin Pharmacol
. 2024 Apr;
80(8):1209-1218.
PMID: 38684558
Background: People with intermediate CVD risk constitute most of the population. Within this group, the proportion of events is lower compared to the high-risk group, but they contribute with the...
6.
Mickelsson M, Ekblom K, Stefansson K, Liv P, Nyman E, Sjalander A, et al.
J Clin Med
. 2024 Apr;
13(5).
PMID: 38592146
The ABO blood group system has previously been associated with cardiovascular disease (CVD), where non-O blood group individuals have shown an increased risk. Studies assessing early atherosclerotic disease while also...
7.
Enblom-Larsson A, Renlund H, Andreasson B, Holmberg H, Liljeholm M, Sjalander A
Br J Haematol
. 2024 Feb;
204(5):1740-1751.
PMID: 38351734
Thromboembolic events and bleeding are known complications in essential thrombocythaemia (ET) and polycythaemia vera (PV). Using multiple Swedish health care registers, we assessed the rate of arterial and venous events,...
8.
Lilja J, Sjalander A, Sjalander S
J Thromb Thrombolysis
. 2023 Sep;
57(1):101-106.
PMID: 37704908
Objectives: To investigate the prevalence of atrial fibrillation (AF), the proportion of AF patients not receiving oral anticoagulation (OAC) and reasons for abstaining from OAC treatment. Methods: A retrospective cross-sectional...
9.
Gummesson C, Alm S, Cederborg A, Ekstedt M, Hellman J, Hjelmqvist H, et al.
BMC Med Educ
. 2023 Sep;
23(1):635.
PMID: 37667366
Background: The development of entrustable professional activities (EPAs) as a framework for work-based training and assessment in undergraduate medical education has become popular. EPAs are defined as units of a...
10.
Welander F, Renlund H, Dimeny E, Holmberg H, Sjalander A
Thromb Res
. 2023 Jul;
229:131-138.
PMID: 37453255
Introduction: Warfarin treatment quality is calculated as time in therapeutic range (TTR). TTR ≥ 70 % is considered reducing the risk of adverse events for patients with atrial fibrillation (AF)....